We recently compiled a list of the 30 Best Stocks To Invest In According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks.

Billionaires and top hedge fund managers dominate the market with large investments in leading companies with strong track records and exceptional performance. These investors have large capital and they like to invest in established companies rather than betting on underperformers.

How’s the Stock Market Performing in 2025 So Far?

The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year post-COVID. Billionaire investor and CEO of Berkshire Hathaway Warren Buffett made a bold move in 2024, selling a record $134 billion of net stock. Buffett’s move has raised concerns for investors and analysts. Historically, when Buffett’s firm becomes a net seller, it’s often followed by below-average market performance. Many believe that this could be a signal of stock market underperformance in 2025.

The stock market has already taken a hit in 2025 following the release of Chinese AI model DeepSeek. Almost $1 trillion was wiped away from the U.S. stock market in January 2025. Now, the market is reacting to President Donald Trump’s tariff policy, as the U.S. initiates 25% tariffs on Canada and Mexico.

“Tariffs increase the odds of a negative feedback loop in the economy. Nobody believed they would be implemented,” said Dennis Debusschere, founder of 22V Research.

The S&P 500 has been underperforming its global peers in 2025 so far, with equity indexes in China, Europe, Canada, and Mexico all racing ahead. S&P 500 has slid nearly 1.90% year-to-date, as of March 4. Whereas, the tech-heavy NASDAQ 100 index has dropped over 4% so far this year.

According to Deutsche Bank strategist Parag Thatte, equity positioning dropped significantly in the week ended February 28, plunging back down to near neutral and wiping out the post-election bump.

Billionaire investor Leon Cooperman in an interview during the Squawk Box show on CNBC recently said that the president is on the right track, but he is doing things in a very destabilizing manner. The president is focusing on reducing the deficit, which is the right thing to do, Cooperman added.

The transition phase seems to have a much bigger impact on the broader market, coupled with the tariff policy. Ironsides Macroeconomics’ Barry Knapp expects the Fed to cut a full percent this year, with the first cut projected in May. Knapp added that the economy needs to shift from government spending to capital spending for a better environment for business.

Our Methodology

For the best stocks to invest in according to billionaires, we analyzed Insider Monkey’s exclusive database of billionaire stock holdings. We selected the 30 best stocks to invest in based on the highest number of billionaire investors, updated as of Q4 2024. For the stocks with the same number of billionaire holdings, we have used the total value of billionaire holdings as a secondary metric to rank the stocks. These billionaires are founders or managers of some of the world’s leading hedge funds and companies. The stocks are ranked in ascending order of the aforementioned metrics.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

An array of pharmaceutical pills with the company's logo on the bottle.

Eli Lilly and Company (NYSE:LLY)

No. of Billionaire Investors: 23

Total Value of Billionaire Holdings: $13.74 Billion

Eli Lilly and Company (NYSE:LLY) is a leading American multinational pharmaceutical company, with a global presence in 18 countries. Its products are distributed in approximately 125 countries, showing its global reach. Eli Lilly and Company aims to pioneer pharmaceutical advancements, as well as focuses on inclusive clinical trials and is committed to ensuring its medicines are both accessible and affordable for diverse populations.

On February 3, Truist Securities analyst Srikripa Devarakonda increased the price target on LLY shares from $1,029 to $1,038 per share, maintaining a Buy rating on the shares. Devarakonda is optimistic regarding the company’s future on the back of strong Q4 and full-year 2024 results. The company posted Q4 revenue of $13.53 billion, surging 45% year-over-year, and full-year revenue increased 32% compared to 2023. The strong growth was driven by the increased sales volume of Mounjaro and Zepbound. The company’s quarterly earnings per share more than doubled, rising 114% to $5.32 per share.

Eli Lilly and Company (NYSE:LLY) stays on the growth trajectory and projects 2025 revenue between $58 billion and $61 billion, reflecting a 32% year-over-year increase. LLY estimates EPS in the range of $22.05 to $23.55, reinforcing confidence in its financial trajectory and continued innovation.

Overall LLY ranks 11th on our list of the best stocks to invest in according to billionaires. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.

 

Disclosure: None. This article is originally published at Insider Monkey.